IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
出版年份 2011 全文链接
标题
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
作者
关键词
-
出版物
LEUKEMIA
Volume 26, Issue 3, Pages 475-480
出版商
Springer Nature
发表日期
2011-09-13
DOI
10.1038/leu.2011.253
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients
- (2011) Mrinal M. Patnaik et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
- (2011) Tatsuhiro Shibata et al. AMERICAN JOURNAL OF PATHOLOGY
- The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
- (2011) C. L. Green et al. BLOOD
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
- (2011) O Abdel-Wahab et al. LEUKEMIA
- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
- (2010) S. Schnittger et al. BLOOD
- Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
- (2010) S. Abbas et al. BLOOD
- The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status
- (2010) C. L. Green et al. BLOOD
- Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
- (2010) F. Thol et al. BLOOD
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
- (2010) F. Thol et al. HAEMATOLOGICA
- Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
- (2010) Nicolas Boissel et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor
- (2010) Katharina Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2010) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
- (2010) Stefan Gross et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q)
- (2010) A Pardanani et al. LEUKEMIA
- IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
- (2010) S Soverini et al. LEUKEMIA
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
- (2010) A Tefferi et al. LEUKEMIA
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
- (2010) D Caramazza et al. LEUKEMIA
- IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
- (2010) A Pardanani et al. LEUKEMIA
- LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
- (2010) A Pardanani et al. LEUKEMIA
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
- (2010) W-C Chou et al. LEUKEMIA
- Deletions of the transcription factor Ikaros in myeloproliferative neoplasms
- (2010) R Jäger et al. LEUKEMIA
- Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms
- (2010) O Kosmider et al. LEUKEMIA
- IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia
- (2010) D Caramazza et al. LEUKEMIA
- Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms
- (2010) Anthony Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
- (2009) A Tefferi et al. LEUKEMIA
- Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
- (2009) A Tefferi et al. LEUKEMIA
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1
- (2009) S. Zhao et al. SCIENCE
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
- (2008) A Tefferi et al. LEUKEMIA
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
- (2008) A M Vannucchi et al. LEUKEMIA
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started